Data Safety Monitoring Board Supports Continuation Of Phase III Clinical Trial Of Medidur(TM) FA For The Treatment Of Diabetic Macular Edema

pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) announced that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has once again recommended that the two pivotal Phase III clinical trials, known collectively as the FAME? (Fluocinolone Acetonide in Diabetic Macular Edema) Study can continue under the current protocol, without change.

More: continued here

Filed under: Eye Health on April 2nd, 2008